U.S. Food and Drug Administration approval: Ruxolitinib for the treatment of patients with intermediate and high-risk myelofibrosis

Clinical Cancer Research

Volumn 18, Issue 12, 2012, Pages 3212-3217

  Deisseroth, Albert ^a   Kaminskas, Edvardas ^a   Grillo, Joseph ^a   Chen, Wei ^a   Saber, Haleh ^a   Lu, Hong L ^a   Rothmann, Mark D ^a   Brar, Satjit ^a   Wang, Jian ^a   Garnett, Christine ^a   Bullock, Julie ^a   Burke, Laurie B ^a   Rahman, Atiqur ^a   Sridhara, Rajeshwari ^a   Farrell, Ann ^a   Pazdur, Richard ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYUREA; KETOCONAZOLE; PLACEBO; RUXOLITINIB;

ANEMIA; ARTICLE; DIZZINESS; DRUG ABSORPTION; DRUG APPROVAL; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FOOD AND DRUG ADMINISTRATION; HUMAN; MYELOFIBROSIS; NEUTROPENIA; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SKIN BRUISING; SPLEEN SIZE; SPLENOMEGALY; THROMBOCYTOPENIA; TOXICITY TESTING; TREATMENT OUTCOME; UNITED STATES; URINARY TRACT INFECTION;

ANEMIA; CLINICAL TRIALS, PHASE III AS TOPIC; DRUG APPROVAL; FEMALE; HUMANS; JANUS KINASE 1; JANUS KINASE 2; MALE; NEUTROPENIA; PRIMARY MYELOFIBROSIS; PYRAZOLES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; THROMBOCYTOPENIA; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84862538656     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-0653     Document Type: Article

References (10)

1. Tefferi A, Barosi G, Mesa RA, Cervantes F, Deeg HJ, Reilly JT, et al. International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT). Blood 2006;108:1497-503. (Pubitemid 44316114)
2. Dupriez B, Morel P, Demory JL, Lai JL, Simon M, Plantier I, et al. Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. Blood 1996;88:1013-8. (Pubitemid 26333326)
3. Tefferi A, Lasho TL, Jimma T, Finke CM, Gangat N, Vaidya R, et al. One thousand patients with primary myelofibrosis: the Mayo Clinic experience. Mayo Clin Proc 2012;87:25-33.
4. Cervantes F, Dupriez B, Pereira A, Passamonti F, Reilly JT, Morra E, et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 2009;113:2895-901.
5. Tefferi A, Lasho TL, Schwager SM, Steensma DP, Mesa RA, Li CY, et al. The JAK2V617F tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates. Br J Haematol 2005;131:320-8. (Pubitemid 43899664)
6. Guglielmelli P, Barosi G, Specchia G, Rambaldi A, Lo Coico F, Antonioli E, et al. Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele. Blood 2009;114:1477-83.
7. Mesa RA, Gotlib JR, Gupta V, DiPersio JF, Kantarjian H, Shields A, et al. Results using the modified myelofibrosis symptom assessment form (MFSAF V2.0) in Comfort-1: a randomized, double-blind phase III trial of JAK1/2 inhibitor ruxolitinib vs placebo in Myelofibrosis [abstract]. In: Proceedings of the 16th Congress of the European Hematology Association; 2011 Jun 9-12; London, UK. Haematologica; 2011. p 380. Abstract nr 912.
8. Mesa RA, Schwager S, Radia D, Cheville A, Hussein K, Niblack J, et al. The Myelofibrosis Symptom Assessment Form (MFSAF): An evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelo fibrosis. Leukemia Res 2009;33: 1199-203.
9. Verstovsek S, Kantarjian H, Mesa RA, Pardanani AD, Cortes-Franco J, Thomas DA, et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med 2010;363:1117-27.
10. Burke LB, Kennedy DL, Miskala PH, Papadopoulos EJ, Trantacosti AM. The use of patient-reported outcome measures in the evaluation of medical products for regulatory approval. Clin Pharmacol Ther 2008;84:281-3.